Interim Report January - June 2002

BIOINVENT INTERIM REPORT 1 JANUARY - 30 JUNE 2002 q BioInvent acquires the rights to develop and commercialise a new type of drug against HIV. q New collaboration agreements with CellControl Laboratories AG and Pharmacia Diagnostics AB will result in high capacity utilisation in the production facility. q In a directed new share issue Oxford GlycoSciences Plc subscribed for 1,331,251 new shares at a price of SEK 39.06 per share. The payment injected funds of SEK 52 million into BioInvent. q Net revenue for January - June 2002 increased to SEK 40.3 million (28.6). q Cash flow from current operations and investment activity, January - June 2002 amounted to SEK 4.1 million (-22,4). Liquid funds at end of period: SEK 394.8 million Loss after net financial items January - June 2002 amounted to SEK -23.9 million (-22.5). Contact: Any questions regarding this report will be answered by: Svein Mathisen, President and CEO, +46 (0)708 97 82 13 Jonas Källmén, CFO, +46 (0)708 77 48 07 The report is also available at: www.bioinvent.com BioInvent International AB (publ.) Company reg. no. 556537-7263 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00580/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00580/wkr0002.pdf The full report